Risk | Low |
---|---|
Min SIP Amount | Not Supported |
Expense Ratio | 0.21% |
NAV | ₹11.48 (19 Apr 2021) |
---|---|
Fund Started | 18 Jun 2018 |
Fund Size | ₹32 Cr |
Name | Sector | Instrument | % Assets |
---|---|---|---|
Sun Pharmaceutical Inds. Ltd. | Healthcare | Equity | 3.6% |
HDFC Bank Ltd. | Financial | Fixed Deposits | 3.6% |
Tata Power Co. Ltd. | Energy | Equity | 3.4% |
ICICI Bank Ltd. | Financial | Equity | 3.0% |
Housing Development Finance Corpn. Ltd. | Financial | Equity | 2.8% |
Dabur India Ltd. | FMCG | Equity | 2.7% |
Cipla Ltd. | Healthcare | Equity | 2.6% |
Lupin Ltd. | Healthcare | Equity | 2.4% |
Siemens Ltd. | Engineering | Equity | 2.2% |
Hindalco Industries Ltd. | Metals | Equity | 2.2% |
BOI AXA Arbitrage Fund Direct Growth is a Equity Mutual Fund Scheme launched by BOI AXA Mutual Fund. This scheme was made available to investors on 18 Jun 2018. Ajay Khandelwal is the Current Fund Manager of BOI AXA Arbitrage Fund Direct Growth fund.The fund currently has an Asset Under Management(AUM) of ₹32 Cr and the Latest NAV as of 19 Apr 2021 is ₹11.48.
The BOI AXA Arbitrage Fund Direct Growth is rated Low risk. Minimum Lumpsum Investment is 500. Exit load of 0.50% if redeemed within 30 days.
The scheme seeks to generate income through arbitrage opportunities between cash and derivative segments of the equity market and arbitrage opportunities within the derivative segment and by deployment of surplus cash in debt securities and money market instruments.